With 60,000+ members, SheMed raises €43 million to advance personalised women’s healthcare in the UK
SheMed, London’s female-founded HealthTech company changing how women access personalised healthcare, today announced it has raised €43 million to further develop its innovative health platform and advance new breakthroughs for preemptive healthcare.
The new funding will be used to expand SheMed’s UK operations, scaling its medical and technology teams, strengthening clinical infrastructure and enhancing its data-driven capabilities.
“For more than a decade, I searched for answers to an undiagnosed health issue,” said Olivia Ferro, Co-founder and CEO of SheMed. “As a GLP-1 patient myself, I know how transformative the right diagnosis and treatment can be. We built SheMed to give women the personalised support I struggled to find: care that listens, understands and empowers.”
The new funding for SheMed fits within a broader wave of 2025 investment activity in UK and European HealthTech, particularly in preventative care and women’s health.
Other UK companies in adjacent areas have also attracted significant capital this year – including Numan, which secured €51.6 million to expand its digital healthcare platform into female health, and Hormona, which raised €7.8 million for its AI-driven hormone health tracking solution.
Related UK-based ventures such as Perci Health and CoMind have also secured fresh capital to advance personalised and data-led healthcare solutions.
According to EU-Startups’ analysis, UK startups collectively raised around €14.7 billion in 2025 to date, signalling sustained investor confidence in the country’s innovation ecosystem.
Within this context, SheMed’s new funding reflects both a strong national momentum and the growing investor recognition of women’s health and metabolic-care platforms as key growth areas in European healthcare innovation.
“The demand for SheMed’s services has been extraordinary,” added Chloe Ferro, Co-founder and President of SheMed. “Women are seeking care that recognises their individuality, their biology and their experiences. It’s why women continue to turn to SheMed for a tailored, more supportive path to healthcare.”
Founded in April 2024 by sisters Olivia and Chloe Ferro, SheMed has grown rapidly to a market frontrunner for its ability to address the persistent gap in women’s healthcare: access to customised, trustworthy and sustainable solutions.
Its programme integrates medical oversight, wellness tracking and 24/7 support through an all-in-one digital platform, ensuring every woman receives tailored individual care while providing a platform that is redefining the healthcare space.
The new investment will also support new research and patient-experience initiatives designed to improve access to high-quality, personalised care for women across the UK.
SheMed is most known for its leading GLP-1 and weight-management platform, which blends medical expertise, data insights and continuous support to help women achieve lasting health results.
In less than a year, SheMed has cared for 60k+ members, reportedly cementing its position as the fastest growing GLP-1 programme in the UK.
Later this month, SheMed will publish results from the first-ever female-focused GLP-1 clinical study, marking a significant milestone in women’s metabolic-health research. The findings will provide insights into how GLP-1 medications affect women’s hormonal and metabolic responses, helping refine future treatment pathways.
The post With 60,000+ members, SheMed raises €43 million to advance personalised women’s healthcare in the UK appeared first on EU-Startups.
